Given the acknowledged lack of success in Alzheimer's disease (AD) drug development
over the past two decades, the objective of this review was to derive key insights from the …

Alzheimer's disease (AD) research has entered a new era with the recent positive phase 3
clinical trials of the anti-Aβ antibodies lecanemab and donanemab. Why did it take 30 years …

Drug repositioning and repurposing can enhance traditional drug development efforts and
could accelerate the identification of new treatments for individuals with Alzheimer disease …

The global impact of Alzheimer's disease (AD) continues to increase, and focused efforts are
needed to address this immense public health challenge. National leaders have set a goal …

Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD)
and to understand the drug development process for new AD therapies. Methods We …

Alzheimer's disease (AD) has no currently approved disease-modifying therapies (DMTs),
and treatments to prevent, delay the onset, or slow the progression are urgently needed. A …

Introduction With the exception of the recent accelerated approval of aducanumab, in over
26 years of research and development (R&D) investment in Alzheimer's disease (AD), only …

A large number of mouse models have been engineered, characterized and used to
advance biomedical research in Alzheimer disease (AD). Early models simply damaged the …

Introduction Recruitment, assessment, and longitudinal monitoring of participants for
neuroscience studies and clinical trials limit the development of new treatments. Widespread …

Introduction Advancing research and treatment for Alzheimer's disease (AD) and the search
for effective treatments depend on a complex financial ecosystem involving federal, state …